Stock Research: Santen Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Santen Pharmaceutical

TSE:4536 JP3336000009
61
  • Value
    65
  • Growth
    16
  • Safety
    Safety
    54
  • Combined
    39
  • Sentiment
    85
  • 360° View
    360° View
    61
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company focused on the research, development, manufacturing, and sales of pharmaceutical products. It operates in medical pharmaceutical, OTC drugs, medical devices, and other businesses, including the cleaning business. The company operates in Japan, Europe, Asia, and North America markets. In the last fiscal year, the company had 3849 employees, a market cap of $3814 million, profits of $1141 million, and revenue of $2001 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 61 (better than 61% compared with alternatives), overall professional sentiment and financial characteristics for the stock Santen Pharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Santen Pharmaceutical. The consolidated Value Rank has an attractive rank of 54, which means that the share price of Santen Pharmaceutical is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 54% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 65. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 85. But the consolidated Growth Rank has a low rank of 16, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 84 of its competitors have better growth. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
54 72 70 77
Growth
16 20 51 43
Safety
Safety
65 61 80 84
Sentiment
85 58 70 27
360° View
360° View
61 55 94 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
66 65 39 31
Opinions Change
44 59 82 50
Pro Holdings
n/a 40 100 37
Market Pulse
79 56 26 47
Sentiment
85 58 70 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
54 72 70 77
Growth
16 20 51 43
Safety Safety
65 61 80 84
Combined
39 50 90 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
68 76 63 78
Price vs. Earnings (P/E)
48 63 62 59
Price vs. Book (P/B)
41 45 56 67
Dividend Yield
62 72 76 88
Value
54 72 70 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
24 4 8 16
Profit Growth
36 58 94 96
Capital Growth
25 23 23 43
Stock Returns
42 46 79 37
Growth
16 20 51 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
61 54 63 74
Refinancing
50 44 63 61
Liquidity
72 64 76 84
Safety Safety
65 61 80 84

Similar Stocks

Discover high‑ranked alternatives to Santen Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Megmilk Snow Brand

TSE:2270
Country: Japan
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Tokuyama

TSE:4043
Country: Japan
Industry: Specialty Chemicals
Size: Medium
Full Stock Analysis

Daicel

TSE:4202
Country: Japan
Industry: Diversified Chemicals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.